BSX vs LLY
BSX: A global medical-device innovator developing minimally invasive solutions for cardiovascular, rhythm management, and endoscopic procedures. LLY: A global pharmaceutical powerhouse developing innovative medicines across cardiometabolic, oncology, and immunology with blockbuster GLP-1 and weight-loss franchises driving exceptional growth.
Side-by-side fundamentals
| Metric | BSX | LLY | Edge |
|---|---|---|---|
| Price as of 2026-07-09 close | $44.99 | $1,216.95 | |
| Market cap as of 2026-07-10 | $66.9B | $1.15T | |
| P/E as of 2026-07-10 | 18.77 | 45.52 | BSX lower |
| PEG as of 2026-07-10 | 0.25 | 1.37 | BSX lower |
| Net margin as of 2026-07-10 | +17.3% | +35.0% | LLY higher |
| Gross margin as of 2026-07-10 | +69.1% | +82.8% | LLY higher |
| Operating margin as of 2026-07-10 | +18.4% | +43.6% | LLY higher |
| ROE as of 2026-07-10 | +14.9% | +101.3% | LLY higher |
| ROA as of 2026-07-10 | +8.3% | +22.7% | LLY higher |
| Debt / equity as of 2026-07-10 | 0.43 | 1.39 | BSX lower |
| Revenue growth (YoY) as of 2026-07-10 | +17.4% | +47.4% | LLY higher |
| Revenue CAGR (3y) SEC XBRL | +16.5% | +31.7% | LLY higher |
| Dividend yield as of 2026-07-10 | +0.0% | +0.6% | LLY higher |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-07-10 | 0.58 | 0.50 | |
| 1-year return as of 2026-07-09 close | -56.2% | +54.6% | LLY higher |
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.